Nitric oxide synthase gene polymorphisms and prostate cancer risk
K.-M. Lee(National Institutes of Health), Richard B. Hayes(New York University), S. I. Berndt(National Institutes of Health), N. Chatterjee(National Cancer Institute), S. K. Park(Seoul National University), Douglas J. Reding(Ascension), Stephen Chanock(National Institutes of Health), Wen‐Yi Huang(National Institutes of Health), Daehee Kang(Seoul National University)
Cited by 76
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k